Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with ...
In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with ...
CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
Over the 48-month period following random assignment, patients in the intention-to-treat (ITT) population who received the combination (n = 323) experienced a mean TFS of 7.0 months compared with 4.6 ...
Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer. Keytruda ...
One of the more challenging genres out there is survival games. These tend to put players in the middle of nowhere with nothing on them, and they must scour to collect as many resources as possible to ...